Recent Investment Analysts’ Ratings Changes for Verastem (VSTM)

A number of research firms have changed their ratings and price targets for Verastem (NASDAQ: VSTM):

  • 6/12/2018 – Verastem was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating.
  • 6/9/2018 – Verastem was given a new $17.00 price target on by analysts at B. Riley. They now have a “buy” rating on the stock.
  • 6/6/2018 – Verastem was upgraded by analysts at ValuEngine from a “buy” rating to a “strong-buy” rating.
  • 5/24/2018 – Verastem was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 5/23/2018 – Verastem was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 5/14/2018 – Verastem was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 5/12/2018 – Verastem was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 5/10/2018 – Verastem was given a new $17.00 price target on by analysts at B. Riley. They now have a “buy” rating on the stock.
  • 5/3/2018 – Verastem had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock. They wrote, “Olga Smolentseva, Ph.D. – (646-975-6966) / [email protected] Our Takeaways From Verastem Investor Day; Reiterate Buy We anticipate duvelisib approval in 4Q18. On May 2, Verastem Oncology held an Analyst and Investor Day in New York and provided an overview on duvelisib’s development and management’s plans for the drug’s commercial launch. Recall, on February 7, Verastem filed a NDA application for duvelisib, the company’s dual PI3K-γ/δ inhibitor, for the treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (r/r CLL/ SLL). The company has also filed for an accelerated approval of duvelisib for the treatment of follicular lymphoma (FL). We note that the FDA has granted a priority review for the duvelisib application, with the PDUFA date scheduled for October 5.””
  • 5/2/2018 – Verastem was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating.
  • 5/2/2018 – Verastem was given a new $17.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 5/2/2018 – Verastem is now covered by analysts at Seaport Global Securities. They set a “buy” rating and a $14.00 price target on the stock.

Verastem traded down $0.06, reaching $5.53, during trading hours on Tuesday, Marketbeat Ratings reports. The company’s stock had a trading volume of 93,454 shares, compared to its average volume of 2,278,112. The stock has a market cap of $325.51 million, a PE ratio of -3.14 and a beta of 2.28. Verastem Inc has a 1 year low of $1.92 and a 1 year high of $6.43. The company has a quick ratio of 4.45, a current ratio of 4.45 and a debt-to-equity ratio of 0.39.

Verastem (NASDAQ:VSTM) last announced its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). sell-side analysts anticipate that Verastem Inc will post -1.48 EPS for the current year.

Large investors have recently bought and sold shares of the stock. AXA raised its holdings in Verastem by 32.2% in the fourth quarter. AXA now owns 78,425 shares of the biopharmaceutical company’s stock worth $241,000 after buying an additional 19,118 shares during the last quarter. Wells Fargo & Company MN raised its holdings in Verastem by 130.5% in the fourth quarter. Wells Fargo & Company MN now owns 45,987 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 26,036 shares during the last quarter. Northern Trust Corp raised its holdings in Verastem by 42.8% in the first quarter. Northern Trust Corp now owns 94,992 shares of the biopharmaceutical company’s stock worth $284,000 after buying an additional 28,473 shares during the last quarter. ClariVest Asset Management LLC raised its holdings in Verastem by 34.6% in the first quarter. ClariVest Asset Management LLC now owns 120,700 shares of the biopharmaceutical company’s stock worth $360,000 after buying an additional 31,000 shares during the last quarter. Finally, SeaCrest Wealth Management LLC purchased a new position in Verastem in the fourth quarter worth about $108,000. 25.63% of the stock is currently owned by institutional investors and hedge funds.

Verastem, Inc, a biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K) signaling pathways. The company's lead FAK inhibitor is defactinib, an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds.

Receive News & Ratings for Verastem Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply